Patents Assigned to AstraZeneca Canada Inc.
  • Novel Compounds with Analgesic Effect
    Publication number: 20080176903
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Application
    Filed: December 5, 2007
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA CANADA INC.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Compounds with analgesic effect
    Patent number: 7312336
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: December 25, 2007
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • G-protein coupled receptor
    Patent number: 7238780
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Grant
    Filed: July 14, 2004
    Date of Patent: July 3, 2007
    Assignee: Astrazeneca Canada Inc.
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • Compounds with analgesic effect
    Patent number: 6974825
    Abstract: Compounds of general formula (I) wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: December 13, 2005
    Assignee: AstraZeneca Canada Inc.
    Inventors: Benjamin Pelcman, Edward Roberts
  • G-protein coupled receptor
    Patent number: 6800749
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: October 5, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • Novel compounds with analgesic effect
    Publication number: 20040171612
    Abstract: Compounds of general formula (I) 1
    Type: Application
    Filed: December 9, 2003
    Publication date: September 2, 2004
    Applicant: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Compounds
    Patent number: 6777561
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: August 17, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun
  • Novel compounds with analgesic effect
    Publication number: 20040138228
    Abstract: Compounds of the formula (I) 1
    Type: Application
    Filed: November 17, 2003
    Publication date: July 15, 2004
    Applicant: AstraZeneca Canada Inc.
    Inventors: Edward Roberts, Niklas Plobeck, Claes Wahlestedt
  • Compounds with analgesic effect
    Patent number: 6710179
    Abstract: Compounds of general formula (I) wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: March 23, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Benjamin Pelcman, Edward Roberts
  • Compounds with analgesic effect
    Patent number: 6693117
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: February 17, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Compounds with analgesic effect
    Patent number: 6680321
    Abstract: Compounds of the formula (I) as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: January 20, 2004
    Assignee: AstraZeneca Canada, Inc.
    Inventors: Edward Roberts, Niklas Plobeck, Claes Wahlestedt
  • Novel galanin receptor
    Publication number: 20030187222
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Application
    Filed: February 6, 2003
    Publication date: October 2, 2003
    Applicant: AstraZeneca Canada Inc.
    Inventors: Shen Shi-Hsiang, Ahmad Sultan, Claes Wahlestedt, Philippe Walker
  • Novel compounds with analgesic effect
    Publication number: 20030149023
    Abstract: Compounds of general formula (I) 1
    Type: Application
    Filed: August 19, 2002
    Publication date: August 7, 2003
    Applicant: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Galanin receptor
    Patent number: 6562945
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: May 13, 2003
    Assignee: AstraZeneca Canada Inc.
    Inventors: Shen Shi-Hsiang, Ahmad Sultan, Claes Wahlestedt, Philippe Walker
  • Compounds with analgesic effect
    Patent number: 6455545
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: September 24, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Thyrotropin-releasing hormone receptor 2(TRHR-2)
    Patent number: 6441133
    Abstract: The present invention is directed to the novel receptor for TRH which has been designated as TRH receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either TRHR-2 proteins or nucleic acids.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: August 27, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventor: Philippe Walker
  • Compounds with analgesic effect
    Patent number: 6399635
    Abstract: Compounds of general formula (I) wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: June 4, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventors: Benjamin Pelcman, Edward Roberts
  • Substituted urea compounds useful in pain management
    Patent number: 6387949
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: May 14, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Niklas Plobeck, Edward Roberts, Eric Sun
  • Compounds useful in pain management
    Patent number: 6376534
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. Intermediates to the compounds of the formula I are also claimed.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Astrazeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun